FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesoph
Go back to FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesoph| Merck & Co. (NYSE: MRK) | Delayed: 125.99 -2.87 (2.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.86 | 52 Week High | $65.46 | |||
| Open | $128.34 | 52 Week Low | $47.97 | |||
| Day High | $128.99 | P/E | 85.71 | |||
| Day Low | $125.14 | EPS | $1.47 | |||
| Volume | 7,910,092 | |||||
